CenExel Clinical acquires Cal. research co.

CenExel Clinical Research Inc., a Salt Lake City company that provides medical and scientific support in the design and execution of clinical trials, has acquired California Neuroscience Research (CNR), a clinical research facility in Los Angeles. CNR has two decades of experience in neurological and psychiatric studies primarily in the areas Alzheimer’s disease, depression, anxiety and migraine pain.

“The acquisition of CNR further strengthens CenExel’s leading central nervous system trial capabilities in the neurology and psychiatry therapeutic areas,” CenExel said in a release. CNR’s Los Angeles location also further expands the CenExel site network patient reach within the second-largest metropolitan area in the U.S. CNR is led by founder Dr. Tom Shiovitz, a board-certified psychiatrist who has more than 30 years of CNS-focused clinical trial research experience.

The CenExel Centers of Excellence network now operates 13 clinical research sites in the country, with emphasis on neurology, pain, psychiatry, vaccines/immunology, dermatology, ethnic-bridging, sleep studies and clinical pharmacology. Each of the CenExel research units has experience assisting pharmaceutical sponsors with protocol development, study design and conducting Phase I-IV trials to develop new therapeutics for improved patient care.

“The CenExel CNR team is very excited to continue our clinical research with the additional resources and strengths the CenExel site network provides,” said Shiovitz.